Additionally, we connect the work of Barili et al. by showing that epigenetic alteration of TP53 pathway genes is dysregulated in conjunction with TBX21, suggesting novel therapeutic combinations that may work to improve outcomes in “inflamed” CRC [37]. The gene discussed is TBX21; the disease is colorectal carcinoma.